ClinConnect ClinConnect Logo
Search / Trial NCT06878781

Postprandial Metabolome and Metabolic Flexibility

Launched by INSTITUTO NACIONAL DE MEDICINA GENOMICA · Mar 10, 2025

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Metabolic Flexibility Postprandial Response Mixed Meals

ClinConnect Summary

This clinical trial is studying how our bodies use different sources of energy after eating meals with varying amounts of carbohydrates, proteins, and fats. The researchers want to understand something called "metabolic flexibility," which is how well our bodies can switch between using these energy sources. This is important because having good metabolic flexibility can help prevent health issues like obesity and diabetes. Participants in the study will eat standardized meals and provide blood samples and other health data to see how their bodies respond.

To be eligible for the trial, participants need to be between 18 and 30 years old, in good health, and not currently using drugs or having any serious medical conditions like diabetes or high blood pressure. Women in the study should have regular menstrual cycles. Participants will be involved for a month, during which they will have their blood tested at different times after eating meals. It's a chance to contribute to important research that could help improve understanding of metabolic health!

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • be over 18 years of age and under 30 years of age;
  • without active drug addictions: smoking, alcoholism, and/or drug addiction;
  • in female subjects: regular menstrual cycles;
  • give written consent for their inclusion in the study.
  • Exclusion Criteria:
  • subjects with any pathology that requires medication or special treatment, such as type 2 diabetes mellitus, high blood pressure, dyslipidemia, polycystic ovary syn-drome, autoimmune, thyroid, kidney, neurological diseases, and cancer;
  • pregnant or lactating women;
  • subjects with problems with chewing, salivation, and swallowing.
  • Elimination criteria:
  • subjects who only have samples (blood and calorimetry) from one study period (fasting or postprandial);
  • subjects who only have samples (blood and calorimetry) of a metabolic challenge;
  • subjects who have an infection at the scheduled appointment;
  • subjects who withdraw their informed consent

About Instituto Nacional De Medicina Genomica

The Instituto Nacional de Medicina Genómica (INMEGEN) is a leading research institution in Mexico dedicated to advancing the field of genomic medicine. Established to promote and conduct cutting-edge research in genomics, INMEGEN focuses on understanding the genetic basis of diseases, improving diagnostic methods, and developing personalized treatment strategies. By fostering collaboration among scientists, healthcare professionals, and industry partners, the institute aims to translate genomic discoveries into practical applications that enhance public health and contribute to the global understanding of human health and disease. Through its robust clinical trial initiatives, INMEGEN plays a pivotal role in the integration of genomic information into clinical practice, ultimately striving to improve patient outcomes and healthcare systems.

Locations

Mexico City, , Mexico

Patients applied

0 patients applied

Trial Officials

Berenice Palacios-Gonzalez, PhD

Principal Investigator

National Institute of Genomic Medicine

Noemi Meraz-Cruz, PhD

Principal Investigator

Universidad Nacional Autonoma de Mexico

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported